U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07163793) titled 'Pilot Study of Reduced Venetoclax Exposure' on Aug. 07.
Brief Summary: A pilot single-arm clinical trial is proposed to assess the primary objective: the tolerability of 14-day Venetoclax cycles in acute myeloid leukemia (AML) patients who have achieved remission and are ineligible for intensive treatment. Participants in the study will transition to a maintenance regimen that reduces the Venetoclax dosage to 14 days per cycle while continuing the hypomethylating agent (HMA) used during induction. Treatment cycles will occur every 28 days. Participants will continue treatment on study until experiencing a grade 4 cytopenic event la...